Cytarabine-daunorubicin

Cytarabine-daunorubicin (CPX-351) is a liposomal encapsulation of cytarabine and daunorubicin that delivers the two compounds in a synergistic 5:1 ratio into leukemia cells to a higher extent than normal bone marrow cells. Cytarabine-daunorubicin can be studied in research on leukemia[1].

Product Specifications

CAS Number

[1256639-86-7]

Product Name Alternative

CPX 351

UNSPSC

12352005

Target

Biochemical Assay Reagents

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](C(C)=O)(O)C[C@@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N.O[C@H]6[C@H](O)[C@H](N7C(N=C(C=C7)N)=O)O[C@@H]6CO

Molecular Formula

C36H42N4O15

Molecular Weight

770.74

References & Citations

[1]Lancet, J. E., et al., (2018) . CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 (26), 2684-2692.